Selected as a finalist for Science to Startup Japan
Radena Sciences, Inc. was selected as a finalist for "Science to Startup (S2S) Japan," sponsored by AN Venture […]
Selected as a pitching company for AMED Seeds Acceleration
Radena Sciences, Inc. has been selected to present at the AMED Seeds Acceleration Pitch, a stage event at the […]
Exhibiting at Japan Healthcare Venture Summit 2025
Radena Sciences, Inc. will be exhibiting at the Japan Healthcare Venture Summit 2025, which will be held at Pa […]
Selected for the acceleration program "Direct Flight"
Radena Sciences, Inc. has been selected for the Boston program of the acceleration program "Direct Flight" by […]
Selected for Rising Biotech Challenge 2025
Radena Sciences, Inc. has been selected for the "Rising Biotech Challenge 2025," a domestic biotech research s […]
Relocation of Head Office
The head office was relocated from Shinjuku-ku, Tokyo to Nihonbashi, Chuo-ku, Tokyo.
A proposal of Masayuki Nakamori (CSO) adopted for AMED research project
A proposal by Masayuki Nakamori, Professor of the Department of Neurology at Yamaguchi University, who also se […]
Selected for the startup support program of Tokyo Metropolitan Government
Radena Sciences, Inc. has been selected for the first startup support program in fiscal year 2023, implemented […]
New Chief Scientific Officer (CSO) Appointed
Professor Masayuki Nakamori of the Department of Neurology at Yamaguchi University was appointed as CSO of our […]
Joint research agreement concluded with the Institute of Scientific and Industrial Research (ISIR: SANKEN), University of Osaka
Radena Sciences, Inc. has signed a collaborative research agreement with Department of Regulatory Bioorganic C […]